Lipitor, Atorvastatin Newswire

Comprehensive Real-Time News Feed for Lipitor, Atorvastatin (generic).

Results 1 - 20 of 465 in Lipitor, Atorvastatin (generic)

  1. Pfizer's second-quarter profit sinks 79 percent but tops forecastsRead the original story

    57 min ago | The Day

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion.

    Comment?

  2. Atorvastatin evokes a serotonergic system-dependent antidepressant-like effect in mice.Read the original story

    3 hrs ago | CiteULike

    Atorvastatin is a statin largely used in the treatment of hypercholesterolemia and recently revealed as a neuroprotective agent.

    Comment?

  3. Pfizer's 2Q profit sinks 79% but tops forecastsRead the original story

    11 hrs ago | Modern Healthcare

    Pfizer's second-quarter earnings plunged 79% from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

    Comment?

  4. Pfizer's quarterly profit sank but topped forecastsRead the original story

    9 hrs ago | Salt Lake Tribune

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a $10 billion-plus gain from a business spinoff.

    Comment?

  5. Pfizer's profit sinksRead the original story w/Photo

    15 hrs ago | Iol.co.za

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion , but results in the most recent quarter still edged analyst expectations.

    Comment?

  6. Pfizer's profit sinks 79% yet still tops forecastsRead the original story

    15 hrs ago | MSN Money

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion.

    Comment?

  7. Pfizer's Second Quarter Profit Sinks 79% But Tops ForecastsRead the original story w/Photo

    15 hrs ago | Pharmaceutical Processing

    Pfizer's second-quarter earnings plunged 79 percent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.

    Comment?

  8. Drugmaker Pfizera s 2nd quarter profit sinks 79 per cent but still beats analyst expectationsRead the original story

    18 hrs ago | 680News

    Pfizer's second-quarter earnings plunged 79 per cent from last year, when the world's second-largest drugmaker booked a business spinoff gain of more than $10 billion, but results in the most recent quarter still edged analyst expectations.

    Comment?

  9. Generic usage increased to more than 75% in the UK in 2013 according to NHS dataRead the original story w/Photo

    21 hrs ago | Medical News Today

    Usage of generic medicines in England and Wales increased to more than three-quarters of all NHS prescriptions in 2013 according to the latest figures supplied by the Health and Social Care Information Centre .

    Comment?

  10. Drugs to increase 'good' cholesterol may not cut deathsRead the original story w/Photo

    Monday | Fox News

    Drugs that have been investigated to increase so-called "good" cholesterol may not prevent deaths, heart attacks or strokes as many hoped, according to a new analysis.

    Comment?

  11. Men who take statins may exercise lessRead the original story

    Sunday | The Times Bulletin

    Older men taking the cholesterol-lowering drugs known as statins appear to be slightly less active than those who don't take them, a new study suggests.

    Comment?

  12. Pfizer's Incoming Patent CliffRead the original story w/Photo

    Thursday Jul 24 | The Motley Fool

    The big pharma giant's loss of patent exclusivity on the world's former top-selling drug, cholesterol fighter Lipitor, has cost its drug revenues dearly.

    Comment?

  13. Hope rises for experimental drugs that lower cholesterolRead the original story w/Photo

    Mar 29, 2014 | WWLP

    A new class of experimental medicines can dramatically lower cholesterol, raising hopes of a fresh option for people who can't tolerate or don't get enough help from Lipitor and other statin drugs that have been used for this for decades.

    Comment?

  14. New Findings from Department of Nephrology Update Understanding of...Read the original story

    Wednesday Jul 23 | Hispanic Business

    Pharmacotherapy with mTOR inhibitors aggravates dyslipidemia, thus necessitating lipid-lowering therapy with fluvastatin, pravastatin, or atorvastatin."

    Comment?

  15. Niacin, Heart Disease And The Fallacy That All Older Drugs Are Safe And EffectiveRead the original story w/Photo

    Wednesday Jul 23 | Forbes.com

    Back in the late 1990s, I became concerned that my LDL cholesterol levels were getting too high.

    Comment?

  16. Studies see new risks for cholesterol drug niacinRead the original story w/Photo

    Monday Jul 21 | The Town Talk

    Pharmacist works at his desk located next to the prescription pick up counter in New York.

    Comment?

  17. Studies see new risks for cholesterol drug niacinRead the original story w/Photo

    Tuesday Jul 22 | The Town Talk

    New details from two studies reveal more side effects from niacin, a drug that hundreds of thousands of Americans take for cholesterol problems and general heart health.

    Comment?

  18. Groupe Athena, Inc Sets Release Date for Year End Financials Release, Reiterates Revenue GuidanceRead the original story

    Monday Jul 21 | MacReport Media RSS Feed

    The UK National Health Service states that it is saving approximately $1million GBP per day on Atorvastatin since the Lipitor The Indian pharmaceutical industry was estimated to be over $21 Billion in 2010 and is expected to experience double digit annual growth through the end of the decade.

    Comment?

  19. Groupe Athena, Inc Sets Release Date for Year End Financials Release, ...Read the original story

    Monday Jul 21 | BayStreet.ca

    MUMBAI, INDIA / ACCESSWIRE / July 21, 2014 / Groupe Athena, Inc. announced today they will release their financial results for the fiscal year ended June 30, 2014 after the close of the market on July 28. In other news, the company states they are making progress with respect to getting the license for Atorvastatin for sale in the U.K. As ... (more)

    Comment?

  20. Lipitor Lawsuits Continue to Be Filed in South Carolina Litigation,...Read the original story w/Photo

    Sunday Jul 20 | PRWeb

    The Firm is actively investigating Lipitor lawsuits on behalf of individuals who allegedly developed Type 2 diabetes due to their use of the cholesterol-lowering statin.

    Comment?